Eli Lilly and Company News - August 4, 2026

Eli Lilly Opens Early Access to Retatrutide for Severe Obesity Patients

Eli Lilly established an expanded access program for its experimental obesity drug, retatrutide, ahead of potential FDA approval. This program provides the...

Eli Lilly and Company Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026

Analysts expect Eli Lilly to report Q2 2026 consensus revenue of $20.65 billion and EPS of $6.71, with the current stock price of $1,121.36 sitting below the...